Goldman Sachs downgraded Option Care Health (OPCH) to Neutral from Buy with a $27 price target. The firm had previously held the view that Option Care’s drugs, including Stelara, were less exposed to gross profit pressure as drugs went generic, but on the Q3 earnings call, management disclosed that Stelara’s manufacturer, Johnson & Johnson (JNJ) had negotiated for a significant and rapid decline in the drug-spread on Stelara for OptionCare in 2025, the analyst tells investors. While Stelara is “unique in size,” its inclusion within the Inflation Reduction Act, the expected pace of pricing declines, and the spread compression precedent created by this situation add incremental risk that other drugs across the portfolio could face similar pressure, notes the firm, which expects these risks will be heightened around several loss-of-exclusivity events upcoming between 2025-2029.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health downgraded to Neutral from Buy at Goldman Sachs
- Option Care Health price target lowered to $34 from $41 at Truist
- Option Care Health price target lowered to $32 from $40 at Barrington
- Option Care Health downgraded to Hold from Buy at Jefferies
- Option Care Health Reports Q3 Revenue Surge Amid Challenges